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17 The serum- and glucocorticoid-induced kinase 1 (SGK1) is a transcriptional target of steroid hormones 
18 including glucocorticoids or aldosterone in addition to other stimuli such as glucose. SGK1 is activated 
19 via phosphoinositide 3-kinase, placing it downstream of insulin signaling. SGK1 participates in the up-
20 regulation of kidney Na+ reabsorption by aldosterone and has been linked to obesity-related hypertension 
21 in humans. We hypothesized that a systemic increase in SGK1 activity may trigger a multiplicity of 
22 mechanisms leading to simultaneous development of the main conditions that characterize the metabolic 
23 syndrome (MetS), including hypertension. We used a transgenic mouse model made with a bacterial 
24 artificial chromosome containing the whole mouse Sgk1 gene modified to introduce an activating point 
25 mutation. Wild type or transgenic fourteen-week old male mice were fed with standard chow diet or high-
26 fat diet for up to 18 weeks. Development of the main features of MetS and hepatic steatosis were 
27 monitored, and in vitro adipocyte differentiation was studied. Our results show that transgenic animals 
28 under high-fat diet rapidly and markedly develop MetS characterized by obesity, glucose intolerance, 
29 insulin resistance, dyslipidemia and hypertension. In addition, SGK1 gain-of-function accelerates the 
30 development of hepatic steatosis. Our study suggests that inappropriate SGK1 activity represents a risk 
31 factor in developing MetS with hypertension and related end organ damage. Our data supports SGK1 as a 
32 possible therapeutic target in MetS and related complications and provides a useful gain-of-function 
33 model for pre-clinical drug testing.
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35 SGK1 is a ubiquitously expressed AGC kinase initially characterized in rat mammary tumor cells 
36 as an immediate early gene induced by serum and glucocorticoids (Webster, et al. 1993). Its expression is 
37 also upregulated by aldosterone (Chen, et al. 1999; Naray-Fejes-Toth, et al. 1999) and other factors 
38 including glucose (Lang, et al. 2006). Once synthesized, SGK1 is activated by insulin and several growth 
39 factors through phosphoinositide 3-kinase, PDK1 and mTORC2 (Garcia-Martinez and Alessi 2008). 
40 Genetic and pharmacological approaches revealed that SGK1 participates in numerous physiological and 
41 pathophysiological processes. Excess activation of SGK1 triggers pro-fibrotic and pro-inflammatory 
42 processes (Artunc and Lang 2014). SGK1 phosphorylates signaling molecules such as GSK3β and 
43 promotes cell survival and proliferation by phosphorylating the FOXO family of transcription factors 
44 (Brunet, et al. 2001). SGK1 has an important role enhancing transepithelial Na+ reabsorption (Chen et al. 
45 1999; Naray-Fejes-Toth et al. 1999; Wulff, et al. 2002) and controlling blood pressure (Norlander, et al. 
46 2017; Pearce 2003; Verrey, et al. 2003). SGK1 knockout mice have normal blood pressure, but are 
47 protected against salt-dependent hypertension in the context of a high-fat diet (Huang, et al. 2006b). In 
48 addition, SGK1 polymorphisms associate to increased blood pressure in humans (Busjahn, et al. 2002), 
49 making carriers more susceptible to blood pressure increase associated to hyperinsulinemia (von Wowern, 
50 et al. 2005). Recent studies show that SGK1 regulates adipocyte differentiation and is expressed in white 
51 adipose tissue (Di Pietro, et al. 2010). The importance of SGK1 in metabolism is further supported by 
52 studies showing that an SGK1 inhibitor reduces blood pressure and body weight in hyperinsulinemic 
53 mice (Ackermann, et al. 2011) and counteracts obesity and hyperglycemia in db/db mice (Li, et al. 2016). 
54 Finally, Sgk1 polymorphisms in humans (E8CC/CT;I6CC) associate with obesity (Dieter, et al. 2004) and 
55 diabetes (Schwab, et al. 2008). In summary, multiple lines of evidence point to the serum and 
56 glucocorticoid-regulated kinase 1 (SGK1) as a common pathway impacting the development of 
57 cardiovascular risk factors such as metabolic disturbances and hypertension. 
58 To date, the effects of excess SGK1 activity on hypertension, obesity and glucose homeostasis 
59 has not been studied. To test whether excess SGK1 activity synergically activates pathways leading to 
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60 hypertension and metabolic alterations, we took advantage of the gain-of-function transgenic Sgk1 mouse 
61 model (Tg.sgk1) previously developed in our laboratory (Andres-Mateos, et al. 2013; Miranda, et al. 
62 2013) in combination with the high-fat diet (HFD)-induced model of obesity and glucose intolerance. Our 
63 results demonstrated exacerbated body weight gain due to fat accumulation, adipocyte hypertrophy, 
64 dyslipidemia and hyperinsulinemia, prominent glucose and insulin intolerance and a rapid development of 
65 hypertension and fatty liver. 
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66 MATERIAL AND METHODS 
67 Mouse model with constitutively active SGK1 expression
68 Experimental procedures involving mice were approved by the University of La Laguna Ethics 
69 Committee on Research and Animal Welfare (permit no. CEIBA2016-0197) and were performed in 
70 accordance with Spanish and European Union regulations (RD53/2013 and 2010/63/EU, respectively). 
71 Generation of transgenic mice expressing a constitutively active mutant of SGK1 (Tg.sgk1) under its own 
72 promoter has been previously described (Andres-Mateos et al. 2013; Miranda et al. 2013). Briefly, a 
73 bacterial artificial chromosome (BAC) containing 180 kbp of mouse genomic DNA that includes the full 
74 Sgk1 gene but no other known or predicted genes was obtained from the BACPAC Resources Center 
75 (Children's Hospital Oakland Research Institute, Oakland, CA). The BAC was modified by homologous 
76 recombination in E. coli to introduce point mutation S422D, which renders the kinase constitutively 
77 active (Kobayashi and Cohen 1999). The purified BAC insert was used for pronuclear injection of 
78 (C57BL/6J × SJL/J) F2 embryos. Founder animals harboring the transgene were backcrossed with 
79 C57BL/6 mice for nine generations to produce the B6.Tg.sgk1 line. Mice homozygous for the transgene 
80 were obtained by crossing heterozygous animals. 
81 Animal procedures
82 Mice were kept in a 14-hour light/10-hour dark cycle at 22°C with ad libitum access to food and water. 
83 Mice were fed a standard chow diet (SCD; Teklad Global Rodent Diet 2014S; 2.9 kcal/g, 13% calories 
84 from fat; 4% fat, 66% carbohydrates, and 14.3% proteins). Twelve-week-old male mice were fed either 
85 SCD or high-fat diet (HFD; Research Diets 12492; 5.24 kcal/g, 60% calories from fat; 34.9% fat, 26.3% 
86 carbohydrate, 26.2% protein) for the time indicated in each experiment. Food intake and body weight 
87 (BW) were measured weekly in mice housed in grouped cages. To study body composition mice were 
88 fasted 3 hours, anesthetized by intraperitoneal injection of ketamine (37.5 mg/kg) combined with 
89 medetomidine (0.5 mg/kg) and examined by dual-energy X-ray absorptiometry (DEXA; Lunar PIXImus 
90 apparatus, GE Medical Systems); anesthesia was reverted with atipamezole (1 mg/kg). Glucose tolerance 
91 tests (GTT) were performed on animals fasted overnight and injected intraperitoneally with a glucose 
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92 bolus (2 g/kg BW). Glycemia was measured before (t=0) and 5, 15, 30, 45, 60, 90 and 120 min after 
93 injection on blood samples obtained by tail massage using a commercial glucometer (OneTouch Ultra, 
94 Johnson & Johnson). Insulin tolerance tests (ITT) were performed on unfasted mice. Insulin was injected 
95 intraperitoneally (0,75 U/kg BW) and blood glucose measurements were performed as in GTT. 
96 Insulinemia was measured using a commercial mouse ELISA Kit (Mercodia). Insulin resistance was 
97 assessed using the homeostasis model assessment (HOMA-IR) (Muniyappa, et al. 2008). Insulin 
98 sensitivity was assessed by the quantitative insulin sensitivity check index (QUICKI) (Bowe, et al. 2014; 
99 Pacini, et al. 2013). Systolic blood pressure (SBP) was measured in trained conscious mice by tail-cuff 
100 plethysmography (LE5007, Panlab Harvard Apparatus) using SeDaCom 2.0 software. Measurements 
101 were collected for three consecutive days after five days of training. SBP was measured at 20 min 
102 intervals for 1 h between 10 and 11 a.m. Mice were euthanized by cervical dislocation. 
103 Plasma and liver biochemistry 
104 At the time of death, blood samples were collected by cardiac puncture in 1.5 ml tubes with 150 μl 5mM 
105 EDTA or heparin (in the case of cholesterol determinations) and plasma was obtained by centrifugation. 
106 Samples were assayed for total insulin (ultrasensitive mouse insulin ELISA Kit, Mercodia), total, HDL 
107 and LDL/VLDL cholesterol (cholesterol assay kit, Abcam), triglycerides (triglyceride quantification kit, 
108 Abcam), glucose and FFA (FFA quantification Kit, Abcam). Liver triglycerides content was measured 
109 using a commercial kit (Abcam).
110 Tissue sampling and histology
111 At sacrifice, fat depots and liver were dissected and weighed. Organs were frozen in liquid nitrogen and 
112 stored at −80°C for molecular analysis or fixed by immersion in 4% formaldehyde, paraffin-embedded 
113 and processed for histology. Microtome 5 µm-thick sections were stained with hematoxylin-eosin 
114 reagent. Sections were coded for unbiased examination. Liver steatosis was evaluated using a 
115 semiquantitative scale adapted from previously validated procedures (Kleiner, et al. 2005). To that end, 
116 images from three different fields in each section were collected at 20x magnification and assigned a 
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117 value in a four-point scale (0, no intracellular lipid drops detected; 1, 2 and 3, progressively increased 
118 abundance of lipid drops; Fig. 4). 
119 Gene expression analysis 
120 Total RNA was extracted from tissues or cells using a commercial kit that includes in-column DNA 
121 digestion (Total RNA spin plus, REAL, Valencia, Spain) and quantified using a Nanodrop 1000 
122 (ThermoFischer Scientific). Relative mRNA abundance was assessed by quantitative RT-PCR (qPCR) 
123 using the comparative Ct method with RPL13A mRNA expression as normalizer. Optimal annealing 
124 temperatures and efficiency was determined for each primer pair. Primers used in this study are listed in 
125 Table 1.
126 Western Blot
127 Protein extracts were obtained from frozen tissue or cells and quantified using the bicinchoninic acid 
128 procedure (Sigma). Equal amounts of protein were resolved on SDS-PAGE (10% Mini-PROTEAN® 
129 TGX Stain-Free™ Gels, Biorad) and transferred to polyvinylidene difluoride membranes (Trans-Blot® 
130 Turbo™ Mini PVDF Transfer Packs Biorad). Western blot analysis was performed as previously 
131 described (Andres-Mateos et al. 2013) using the antibodies listed in Table 2. Signals were acquired with 
132 luminesce detector (ChemiDoc™ Touch Imaging System, Biorad) and quantified using software provided 
133 by the manufacturer.
134 In vitro pre-adipocyte differentiation
135 Vascular stromal cell fraction from WT or Tg.sgk1 mice was prepared from pooled fat pads (inguinal, 
136 axillar, epididymal and perirenal) and cultured as described (Desarzens and Faresse 2016). Cells were 
137 allowed to reach confluence and the differentiation process was initiated using DMEM supplemented 
138 with 10% fetal bovine serum (FBS) 500 µM 3-isobutyl-1-methylxanthine, 1 µg/ml insulin, 250 nM 
139 dexamethasone and 2 µM rosiglitazone for 2 days. Cells were then grown in DMEM supplemented with 
140 10% FBS, 1 µg/ml insulin for an additional 2 days. Experiments were performed once the cells were fully 
141 differentiated (around day 20) and clear lipid droplets were observed. For determination of lipid content, 
142 cells were fixed in 4% paraformaldehyde in PBS, washed twice with water and once with 60% 
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143 isopropanol, and stained with Oil-Red-O. After excess Oil-Red-O removal and washes with water, the 
144 stained cells were permeabilized with 100% isopropanol and 10% SDS and Oil-Red-O in the eluate was 
145 measured by spectrophotometry at 520 nm.
146 Glucose and FFA uptake       
147 Undifferentiated and differentiated adipocytes from WT and B6.Tg.sgk1 mouse were cultured for 24 h 
148 without serum. Cells were washed with Krebs-Ringer buffer containing 12 mM HEPES and 0.1% BSA 
149 (KRH-BSA) and then treated with 100 nM insulin for 30 min. Glucose uptake was initiated by addition of 
150 1µCi/well of [3H]-deoxy-D-glucose. After 5 min incubation cells were washed 3 times with ice-cold 
151 KRH-BSA. FFA uptake was initiated by addition of 1µCi/well of [1-14C]-palmitic acid for 5 minutes and 
152 stopped by washing cells 3 times with ice-cold KRH-BSA. In both cases, cells were then lysed with 0.1 
153 M NaOH and radioactivity was measured by scintillation counting. In parallel, protein concentration in 
154 each sample was measured using the Bradford method. 
155 Statistical analysis
156 Data are reported as average ± SE. Statistical analysis was performed with Prism 7 software (Graphpad). 
157 Statistical tests used for analysis are specified in each figure legend.
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159 Constitutively active SGK1 expression exacerbates HFD-induced obesity, adipocyte hypertrophy 
160 and inflammation
161 To test the effects of constitutive SGK1 activation on HFD-induced obesity, we fed 14-week-old wild 
162 type (WT) or Tg.sgk1 mice either with a standard chow diet (SCD) or a high-fat diet (HFD) for up to 6 
163 weeks. At the end of this period mice fed SCD did not show any difference in total body weight, although 
164 Tg.sgk1 had a higher fat content, suggesting a predisposition to obesity (Table 3). HFD induced a faster 
165 weight gain in transgenics when compared to WT mice (Fig. 1A). The dramatic increase of BW gain in 
166 transgenic mice fed with HFD was not due to hyperphagia since food intake was even lower than WT 
167 mice (Fig. 1B). The observed BW differences were due to fat accumulation, as determined by DEXA 
168 (Fig. 1C and Table 3) or by individual dissection of fat pads (Fig. 1D). Histological analysis of 
169 epididymal adipose tissue revealed prominent adipocyte hypertrophy after 6 weeks of HFD in transgenic 
170 animals when compared to WT, with fewer adipocytes/area (Fig. 1E) and adipocyte area frequency 
171 distribution skewed towards larger values (Fig. 1F). Quantitative analysis of mRNA expression showed 
172 that white adipose tissue displays increased expression of SGK1, which is expected due to the increase 
173 gene dosage provided by the BAC insertion (Fig. 1G). Endogenously expressed Nedd4-2, a well-known 
174 SGK1 target (Debonneville, et al. 2001), showed increased phosphorylation in white adipose tissue from 
175 Tg.sgk1 mice when compared to WT, consistent with the expression of a constitutively active SGK1 (Fig. 
176 1H). Adipocyte hypertrophy contributes to unfavorable metabolic changes (Sun, et al. 2011). To test 
177 whether fat pad expansion and adipocyte hypertrophy correlated with increased inflammation, we 
178 analyzed expression of inflammation markers in epididymal fat. No difference between WT and Tg.sgk1 
179 mice was observed under SCD (Fig. 1I). HFD increased expression of all inflammation markers in both 
180 WT and Tg.sgk1 mice (Fig. 1I). However, Tg.sgk1 mice showed significantly higher expression of IL-6, 
181 TFN and MCP-1, suggesting increased adipose tissue inflammation.
182 Constitutive activation of SGK1 promotes insulin-induced glucose and free fatty acids (FFA) 
183 uptake in primary adipocytes
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184 To test whether adipocyte hypertrophy observed in Tg.sgk1 mice was due to increased nutrient uptake, 
185 we measured glucose and FFA uptake in vitro using differentiated adipocytes from adipose vascular 
186 stromal cells. Insulin-induced glucose and FFA uptake was higher in differentiated adipocytes derived 
187 from transgenic mice (Fig. 2A,B). At the molecular level, glucose transporter GLUT4 and lipid 
188 transporter CD36 expression levels were also significantly higher in cells derived from Tg.sgk1 mice 
189 (Fig. 2C,D), suggesting that SGK1 activation promotes adipocyte differentiation and lipid accumulation. 
190 This hypothesis was confirmed by the higher lipid accumulation (Fig. 2E,F) and adipogenesis marker 
191 expression (Fig. 2G) in cells derived from transgenic mice. Taken together, these data indicate that 
192 increased expression of SGK1 enhances adipogenesis and increases uptake of FFAs and glucose, possibly 
193 by up-regulating membrane transporters. 
194 Dyslipidemia, glucose intolerance and insulin resistance in HFD-fed Tg.sgk1 mice
195 Adipocyte hypertrophy and low-grade inflammation are closely associated with the development of 
196 dyslipidemia and insulin resistance (Kim, et al. 2015; Shoelson, et al. 2006). To investigate whether the 
197 exacerbated obese phenotype observed in Tg.sgk1 mice correlated with larger metabolic disturbances, 
198 several metabolic parameters were measured in the plasma of SCD- or HFD-fed WT and Tg.sgk1 mice. 
199 Under fed conditions, HFD-fed transgenic mice showed significantly higher levels of insulin and 
200 triglycerides and decreased levels of HDL cholesterol (Table 3). Under fasting condition, Tg.sgk1 
201 maintained their hyperinsulinemia as well as hyperglycemia (Table 3). In addition, SCD-fed transgenics 
202 also show increased fasting glucose (Table 3) and a positive correlation between glycemia and BW (Fig. 
203 3A), suggesting an impairment of glucose homeostasis that is exacerbated under HFD. Accordingly, 
204 transgenic animals displayed a significantly impaired response to a glucose challenge after 5 weeks in 
205 HFD (Fig. 3B,C). ITT revealed that after 6 weeks in HFD Tg.sgk1 mice show decreased sensitivity to 
206 insulin (Fig. 3D,E). In agreement with these observations, HOMA index was increased in Tg.sgk1 
207 compared to WT mice (Table 3). Transgenics also displayed decreased QUICKI values (Table 3). 
208 Analysis of insulinemia during GTT showed that glucose-stimulated insulin secretion was affected in 
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209 Tg.sgk1 mice (Fig. 3F,G). This indicates that transgenic animals with excess SGK1 and fed a HFD are 
210 insulin resistant with advanced diabetic features.
211 Insulin resistance was further confirmed by studying the insulin signaling pathway in epididymal 
212 adipose tissue of HFD-fed animals. Despite significantly increased insulin receptor expression, Tg.sgk1 
213 mice showed a significant reduction in phosphorylation of downstream effectors IRS1, protein kinase 
214 AKT and its substrate AS160 (Fig. 3H,I). This observation confirmed that defects responsible for insulin 
215 resistance occurred at the post-receptor level as previously described (Draznin 2006; Kolterman, et al. 
216 1980).
217 Non-alcoholic fatty liver (NAFL) in HFD-fed Tg.sgk1 mice
218 In order to check whether the metabolic disorders induced by HFD in Tg.sgk1 mice accelerates the 
219 development of NAFL, we analyzed lipid accumulation by histological analysis of liver sections. We first 
220 confirmed increased SGK1 expression in the liver of transgenics. Total SGK1 mRNA abundance was 
221 increased by 60% in Tg.sgk1 compared to WT mice under SCD (Fig. 4A). Tg.sgk1 mice treated with 
222 HFD showed 2.8-fold increased expression of SGK1, suggesting that constitutively active SGK1 may 
223 potentiate its own expression under these conditions (Fig. 4A). Phosphorylation of a well-known 
224 downstream target of SGK1, glycogen synthase kinase 3 (GSK3) (Wyatt, et al. 2006), was also increased 
225 in Tg.sgk1 (Fig. 4B). Hematoxylin-eosin staining revealed that after 6 weeks of HFD Tg.sgk1 livers 
226 presented severe micro- and macro-vesicular steatosis with marked hepatocellular ballooning, while WT 
227 mice presented less affected livers with micro-vesicular steatosis only. Semiquantitative analysis of the 
228 extent of lipid inclusion supported widespread presence of NAFL in HFD-fed Tg.sgk1, but not in WT 
229 animals (Fig. 4C, D). Biochemical analysis of liver tissue composition confirmed the significantly higher 
230 triglycerides content in Tg.sgk1 mice livers (Fig. 4E).
231 HFD-fed Tg.sgk1 mice rapidly develop hypertension
232 To test whether SGK1 gain-of-function induces hypertension, we compared SBP measurements in WT 
233 and transgenic mice before and after HFD feeding. Animals kept in SCD did not show any differences on 
234 SBP between genotypes at 12 weeks of age (Fig. 5), or at later time points, even when challenged with 
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235 high NaCl intake (data not shown). Remarkably, HFD produced a significant increase on SBP in 
236 transgenic mice after 4 weeks of HFD. Tg.sgk1 SBP continued increasing over time to reach an average 
237 of 173 mmHg after 7 weeks on HFD and 184 mmHg after 18 weeks, approximately 40-50 mmHg higher 
238 than WT (Fig. 5). After 18 weeks of HFD WT animals also showed significantly elevated SBP when 
239 compared to animals on SCD (Fig. 5). Therefore, excess SGK1 sensitizes mice to rapidly developing 
240 hypertension when fed HFD. 
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242 SGK1 as a risk factor for obesity and MetS 
243 Available information strongly supports the idea that SGK1 constitutes a convergence point linking 
244 obesity, metabolic alterations and hypertension, all clustered in the so-called MetS. From a mechanistic 
245 standpoint, these effects appeared to be multifactorial (see below). Therefore, our mouse model with 
246 systemic SGK1 expression under its own promoter but harboring a gain-of-function mutation appeared 
247 ideally suited to evaluate the role of this kinase in a complex and multi-organ condition such as the MetS. 
248 We found that excess SGK1 activity promotes adiposity together with hyperglycemia under a standard 
249 chow diet. The full deleterious effects of SGK1 were triggered by increased fat intake, leading to a very 
250 rapid and prominent development of other MetS components, most notably hypertension. This conclusion 
251 validates our hypothesis that a systemic increase in SGK1 activity constitutes a risk factor for metabolic 
252 disorders progression.
253 The adipose tissue was considered for a long time to be a passive fat storage compartment, but 
254 nowadays it is regarded as a versatile and central organ in the development of metabolic disorders. SGK1 
255 is overexpressed in adipose tissue in obese mice and humans (Li, et al. 2013) and it participates in HFD-
256 induced adipogenesis (Ding, et al. 2017).  Our results using a gain-of-function SGK1 mutation support 
257 the involvement of SGK1 in adipocyte differentiation in vitro, as previously described in Sgk1 knockout 
258 mouse model (Di Pietro et al. 2010). We found that activated SGK1 promotes lipid accumulation within 
259 the cytoplasm, probably due to increased glucose and FFA uptake. However, the role of SGK1 in energy 
260 metabolism is likely not restricted to adipocytes. SGK1 is also expressed in the liver, where it has been 
261 shown to regulate insulin sensitivity (Liu, et al. 2014). Our data also suggests hepatic effects of SGK1, 
262 based on the hypertriglyceridemia detected under HFD and also the rapid development of NAFL. 
263 However, additional investigations are needed to decipher whether SGK1 has a direct effect on 
264 hepatocytes or an indirect effect related to the observed dyslipidemia leading to ectopic fat deposition. In 
265 skeletal muscle, SGK1 appears to be involved in increasing glucose transporter expression, glucose 
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266 uptake and glycogen accumulation (Singh, et al. 2013). Finally, a recent report showed that specific 
267 deletion of Sgk1 in POMC neurons increases adiposity induced by glucocorticoids (Deng, et al. 2018). 
268 The metabolic roles of SGK1 are added to its role in renal Na+ handling and blood pressure 
269 control. Sgk1 knockout animals do not shown altered SBP under normal conditions, but display impaired 
270 aldosterone-mediated increase in Na+ reabsorption, leading to decreased blood pressure under low salt 
271 intake (Faresse, et al. 2012; Wulff et al. 2002). SGK1 mediates the synergistic effect of insulin on 
272 aldosterone-induced Na+ reabsorption through the epithelial Na+ channel (Alvarez de la Rosa and Canessa 
273 2003; Wang, et al. 2001). Recently, Norlander et al, showed that specific deletion of SGK1 in T cells 
274 blunts the increase in blood pressure in both the angiotensin II and DOCA/salt models of hypertension 
275 (Norlander et al. 2017), pointing to a multiplicity of mechanisms by which SGK1 may regulate blood 
276 pressure. Crucially, SGK1 knockout mice are protected against salt-dependent hypertension in the context 
277 of a high-fat (Huang et al. 2006b) or high-fructose diets (Huang, et al. 2006a).  In addition, SGK1 
278 polymorphisms associate to increased blood pressure in humans (Busjahn et al. 2002), making carriers 
279 more susceptible to blood pressure increase associated to hyperinsulinemia (von Wowern et al. 2005). 
280 Our results represent the first analysis of increased SGK1 effects on blood pressure. In the absence of a 
281 challenge, SBP in transgenic animals is indistinguishable from WT. However, HFD produced a very rapid 
282 and large increase in blood pressure, in agreement with the notion that excess SGK1 activity may 
283 constitute a risk factor to develop hyperinsulinemia-related hypertension. Remarkably, in the absence of 
284 obesity and metabolic disturbances, a high-salt intake challenge did not raise SBP, suggesting that the 
285 coordinated activity of SGK1 in different tissues, and not just in the kidney, is responsible for this effect. 
286 The effects of increased SGK1 activity on blood pressure after a combined challenge of high-salt and 
287 high-fat intake remains to be determined.  
288 The relevant upstream stimuli upregulating SGK1 expression in adipose tissue of mouse models 
289 of obesity as well as obese and diabetic patients remain elusive (Li et al. 2013). Transcription of this 
290 kinase is regulated by several factors, including corticosteroids acting through the glucocorticoid and 
291 mineralocorticoid receptors (GR and MR, respectively) (Chen et al. 1999; Naray-Fejes-Toth et al. 1999; 
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292 Webster et al. 1993). Systemic glucocorticoid excess such as during Cushing syndrome reproduce the 
293 main characteristics of MetS (Newell-Price, et al. 2006). Several lines of evidence support a key role for 
294 both GR and MR in the pathogenesis of MetS by acting on several targets including the adipocyte, 
295 although there is conflicting evidence regarding the relative roles of each on adipocyte differentiation and 
296 function (Desarzens and Faresse 2016; Gomez-Sanchez 2015; Lee, et al. 2014; Marzolla, et al. 2012; 
297 Urbanet, et al. 2015). Remarkably, the use of a combined GR/MR antagonist significantly reduced the 
298 development of obesity in mice under HFD (Mammi, et al. 2016). Our results suggest that at least some 
299 of the deleterious effects of GR/MR activation may be mediated through SGK1. 
300 SGK1 inhibition as a possible strategy to treat obesity-related hypertension
301 Our study, together with previously available evidence, suggests that SGK1 is a potential target to treat 
302 obesity-induced hypertension. HFD-fed Sgk1 knockout mice are resistant to salt-sensitive hypertension, 
303 but not to hypertension induced by HFD alone (Huang et al. 2006b). Similarly, Sgk1 knockout mice are 
304 resistant to moderate increases in blood pressure induced by combined high-fructose and high-salt intake 
305 (Huang et al. 2006a), suggesting that the hypertensive effect of hyperinsulinemia may be associated to 
306 SGK1. In this context, preliminary studies using the SGK1 inhibitor EMD638683 lowered blood pressure 
307 in mice fed a high-fructose, high-salt diet (Ackermann et al. 2011). Furthermore, SGK1 inhibition showed 
308 beneficial effects in the development of obesity and hyperglycemia in db/db mice (Li et al. 2016). 
309 However, Sgk1 knockout mice also show glucose intolerance and insulin resistance (Huang et al. 2006b), 
310 which could present a problem in long-term treatments inhibiting the kinase. In addition, the development 
311 of SGK1 inhibitors would have to overcome cross-reactivity with related kinases, including isoforms 
312 SGK2, SGK3 and AKT (Ackermann et al. 2011).
313 A new mouse model for MetS, related comorbidities and end organ damage
314 One important observation made in this study is that HFD-fed Tg.sgk1 mice develop MetS features closer 
315 to the ones observed in humans, more rapidly and prominently than most available models. The 
316 availability of suitable rodent models to study the pathophysiological and molecular mechanisms of MetS 
317 progression is limited and most of them do not exhibit the entire clinical features observed in humans. 
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318 The existing mouse models of MetS present several shortcomings, including the inconsistency of 
319 hypertension development in obese mice (Kennedy, et al. 2010). Most models show coincident obesity 
320 and insulin resistance. However, the simultaneous presence of these two characteristics with dyslipidemia 
321 and hypertension is more difficult to achieve. In WT mice, 4 months of HFD raised the systolic blood 
322 pressure by 30-40 mmHg, confirming previous studies (Gupte, et al. 2008; Marshall, et al. 2013), 
323 although in other reports even this long treatment is not enough to raise blood pressure (Police, et al. 
324 2009). In Tg.sgk1 mice, a similar increase was reached after only 4 weeks of HFD and dramatically 
325 increased at longer time points. In addition to hypertension, all features of MetS appeared faster and more 
326 severe in our model. NAFL, a comorbidity commonly co-existing with MetS and hypertension (Cornier, 
327 et al. 2008), is also accelerated in our model. Our results and other studies showed that 6 weeks of HFD 
328 has no effect on hepatic triglyceride levels in WT mice (Nam, et al. 2015; Yamaguchi, et al. 2007). In 
329 contrast, the same period of high-fat feeding induces hepatic triglycerides accumulation in Tg.sgk1 
330 comparable to levels found in C57BL/6 mice after 12 weeks in HFD (Nam et al. 2015). 
331 Limitations of this study and perspectives
332 For practical reasons, our study included only male mice. Based on the known sexual dimorphism in 
333 susceptibility to obesity in mice (Hong, et al. 2009), additional experiments are needed to test the effects 
334 of  excess SGK1 activity on female mice. Also, it should be noted that a common weakness in studies 
335 using HFD vs. standard chow is that diets are not isocaloric and matched for ingredients. Therefore, other 
336 ingredients varying between diets may also contribute to the phenotype described here. Most importantly, 
337 the effects of SGK1 described here are likely due to synergistic mechanisms affecting among others 
338 energy storage, insulin signaling and renal Na+ handling.  Dissection of the relative importance of these 
339 mechanisms will need the development of tissue-specific conditional SGK1 gain-of-function models 
340 together with already available Sgk1 knockout lines. 
341 From a translational perspective, our data further supports the idea of SGK1 as a possible 
342 therapeutic target in MetS, particularly in situations where obesity co-exists with hypertension. Due to the 
343 fast and complete development of MetS with hypertension after a short HFD treatment, we propose that 
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344 the SGK1 systemic gain-of-function model constitutes a useful experimental in vivo model for pre-
345 clinical drug testing.
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509 Figure 1. Constitutively active SGK1 exacerbates diet-induced obesity, adipocyte hypertrophy and 
510 adipose tissue inflammation. A, BW variation in aged-matched WT or Tg.sgk1 mice fed with a high-fat 
511 diet (HFD). Data points represent average weekly cumulative weight gain ± SE (N=39 for WT; N=43 for 
512 Tg.sgk1). Two-way ANOVA followed by Tukey’s multiple comparison test (*p<0.05, ***p<0.001). B, 
513 Average ± SEM food intake/day in animals fed with SCD or HFD (N=5 for SCD; N=15 for WT HFD 
514 group; N=18 for Tg.sgk1 HFD; **p<0.01, Student´s t test).  C, Representative images of body 
515 composition analysis by DEXA in anesthetized mice. D, Average epididymal and mesenteric adipose 
516 tissue weight ± SEM (N=6) normalized to total body weight of WT and Tg.sgk1 mice kept on SCD or 
517 after 6 weeks on HFD (*p<0.05, ***p<0.001, ****p<0.0001, one-way ANOVA followed by Tukey’s 
518 multiple comparison test). The weight of inguinal fat in mice kept in SCD was not determined (n.d.). E, 
519 Representative micrographs of hematoxylin-eosin stained epididymal white adipose tissue obtained from 
520 WT or Tg.sgk1 mice kept under SCD or fed a HFD for 6 weeks. Bar, 40 m. F, Frequency histogram 
521 with Gaussian distribution fit showing percentage of adipocytes from HFD-fed animals in each area 
522 category (N=6). Dashed lines, median values for WT and Tg.sgk1 adipocyte area. ***p<0.001, Mann-
523 Whitney test. G, SGK1 mRNA expression in epididymal fat of WT and Tg.sgk1 mice under SCD or 
524 HFD. Values represent average ± SEM (N=6). *p<0.05, one-way ANOVA followed by Sidak’s multiple 
525 comparison test. H, Representative immunoblot detecting total and phospho-S488 Nedd4-2 in protein 
526 extracts obtained from epididymal fat of WT or Tg.sgk1 mice. I, Relative mRNA expression of 
527 inflammation markers in epididymal fat of WT and Tg.sgk1 mice under SCD or HFD. Values represent 
528 average ± SEM (N=6). nd, non-detectable. IL-1, interleukin 1; IL-6, interleukin 6; TNFα, tumor necrosis 
529 factor α; CD68, cluster of differentiation 68; MCP1, monocyte chemoattractant protein-1. *p<0.05, 
530 **p<0.01, one-way ANOVA followed by Sidak’s multiple comparison test.
531 Figure 2. Increased SGK1 increases glucose and free fatty acids (FAA) uptake and accelerates in 
532 vitro adipocyte differentiation. Basal and insulin-induced glucose (A) or FAA (B) uptake in 
533 undifferentiated and differentiated adipocytes obtained from WT or Tg.sgk1 mice. Bars represent average 
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534 ± SEM (N=4) incorporated radioactivity normalized to protein concentration. Student’s t test, *p<0.05. 
535 Glucose transporter GLUT4 (C) and lipid transporter CD36 (D) mRNA expression at Day 0 and Day 7 
536 during differentiation. Values are average ± SEM (N=4). Student’s t test; **, p<0.01. E, Oil red-O 
537 accumulation in undifferentiated or differentiated cells. F, Symbols represent individual oil red-O 
538 absorbance values at 520 nm from four independent experiments; *, p<0.05; ***, p<0.001 (two-way 
539 ANOVA followed by Sidak’s multiple comparison test). G, Lipogenic marker expression during 
540 differentiation. Values are average ± SEM normalized to RPL13A. PPARγ, peroxisome proliferator 
541 activated receptor γ; CEBPα, CCAAT-enhancer binding protein α; LPL, lipoprotein lipase. Two-way 
542 ANOVA followed by Sidak’s multiple comparison test: *, p<0.05; **, p<0.01; ***, p<0.001.
543 Figure 3.  Tg.sgk1 mice show impaired glucose tolerance and insulin resistance. A, Positive 
544 correlation between body weight and fasting glycemia in Tg.sgk1, but not in WT mice fed SCD. 
545 Spearman correlation: WT, p=0.084; Tg.sgk1, p=0.029. Linear correlation slope in Tg.sgk1=3.91.6 
546 (p=0.03); linear correlation slope in WT mice was not significantly different from zero (p=0.128). B, 
547 Glucose tolerance test (GTT) in WT and Tg.sgk1 kept in SCD or fed HFD for 5 weeks. Values are 
548 average glycemia ± SEM at the indicated time point after glucose load (N=14; WT SCD; N=13, Tg.sgk1 
549 SCD; N=23, WT HFD; N=26, Tg.sgk1 HFD). Two-way ANOVA followed by Tukey´s multiple 
550 comparison test (Tg.sgk1 HFD vs. Tg.sgk1 SCD, *p<0.05; Tg.sgk1 HFD vs. WT HFD, #p<0.05; WT 
551 HFD vs. WT SCD, &p<0.05; Tg.sgk1 SCD vs. WT SCD, +p<0.05; for simplicity the other three 
552 comparisons are not shown). C, Individual points represent area under the curve (AUC) values obtained 
553 from each mice in the GTT curves shown in panel B. Average ± SEM AUC are also indicated. One-way 
554 ANOVA followed by Tukey’s multiple comparison test:  **p<0.01, ***p<0.001). D, Insulin Tolerance 
555 Test (ITT). Values represent average glycemia ± SEM (N=16) at the indicated time point after insulin 
556 injection. Two-way ANOVA followed by Tukey´s multiple comparison test (Tg.sgk1 HFD vs. Tg.sgk1 
557 SCD, *p<0.05; Tg.sgk1 HFD vs. WT HFD, #p<0.05; WT HFD vs. WT SCD, &p<0.05; for simplicity the 
558 other three comparisons are not shown; there were no significant differences between Tg.sgk1 and WT in 
559 SCD). E, Individual points represent area under the curve (AUC) values obtained from each mice in the 
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560 ITT curves shown in panel D. Average ± SEM AUC are also indicated. One-way ANOVA followed by 
561 Tukey’s multiple comparison test; (*p<0.05, **p<0.01, ***p<0.001). F, Average insulinemia ± SEM at 
562 the indicated time points during GTT in mice fed with SCD or with HFD for 5 weeks (N=7, WT; N=11, 
563 Tg.sgk1). Two-way ANOVA followed by Tukey’s multiple comparison test: Tg.sgk1 HFD vs. Tg.sgk1 
564 SCD,  **p<0.01, ***p<0.001; Tg.sgk1 HFD vs. WT SCD, ++p<0.01, +++p<0.001; Tg.sgk1 HFD vs. WT 
565 HFD, ##p<0.01, ###p<0.001. G, Individual points represent area under the curve (AUC) values obtained 
566 from each mice in the insulinemia curves shown in panel F. Average ± SEM AUC are also indicated. 
567 One-way ANOVA followed by Tukey’s multiple comparison test; (*p<0.05, **p<0.01, ***p<0.001). H, 
568 Insulin signaling pathway analyzed by western blot of epididymal adipose tissue from WT and Tg.sgk1 
569 mice after 6 weeks on HFD (N=5). Each lane corresponds to a sample from one animal. InsR, insulin 
570 receptor; IRS1, insulin receptor substrate 1; AS160, AKT substrate of 160 kDa. I, Quantitative analysis of 
571 western blots shown in panel H. Values represents average ± SEM (Student’s t test, *p<0.05).
572 Figure 4. HFD produces liver steatosis in Tg.sgk1 mice. A, Relative SGK1 mRNA expression in liver 
573 of WT and Tg.sgk1 mice under SCD or HFD. Values represent average ± SEM (N=5-7). *p<0.05, one-
574 way ANOVA followed by Sidak’s multiple comparison test. B, Representative immunoblot detecting 
575 phosphorylated GSK3 at residue S9 and total GSK-3 in liver protein extracts from three different WT 
576 and Tg.sgk1 mice. C, Representative images of hematoxylin-eosin-stained liver sections from WT or 
577 Tg.sgk1 mice fed a HFD for 6 weeks. D, Semiquantitative analysis of lipid deposition in liver sections. 
578 Each bar represents the percentage of animals included in each score category (-, no lipid drops; +, ++, 
579 +++, increasing amounts of lipid drops). N=6. E, Hepatic triglyceride content. Bars represent average ± 
580 SEM normalized to tissue weight (N=7, WT; N=9, Tg.sgk1). *p<0.05, Student’s t test.
581 Figure 5. Excess SGK1 activity induces hypertension in HFD-fed mice. Individual points represent 
582 systolic blood pressure (SBP) obtained using the tail-cuff method on 12-week-old WT and Tg.sgk1 mice 
583 kept on SCD or after the indicated time on HFD (N=9, SCD; N=10, HFD, 4 weeks; N=7, WT HFD, 7 
584 weeks; N=11, Tg.sgk1 HFD, 7 weeks; N=4, WT HFD, 18 weeks; N=6, Tg.sgk1 HFD, 18 weeks). 
585 Average values ± SEM are also represented. Two-way ANOVA followed by Bonferroni´s multiple 
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586 comparison test (WT vs. Tg.sgk1: n.s., no significant difference; *p<0.05; **p<0.01; ***p<0.001. 
587 +p<0.05, WT SCD vs. WT 18 weeks HFD. #p<0.05, ###p<0.001, Tg.sgk1 SCD vs. HFD).
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Synthetic peptide surrounding 











Rabbit polyclonal 1:1000 AB_10890702
GSK3-β






Rabbit monoclonal 1:1000 AB_490890
pGSK3α/β















Abcam Mouse monoclonal 1:500 AB_1209215
p-IRS1
Peptide containing human 




Rabbit polyclonal 1:1000 AB_669445
IRS1
Synthetic peptide conjugated to 
KLH, surrounding amino acids 
634-638 of Human IRS1
Anti-IRS1 
antibody
Abcam Rabbit polyclonal 1:500 AB_11156316
p-AKT T308
Synthetic phosphopeptide 





Rabbit polyclonal 1:1000 AB_329828
p-AKT S473
Synthetic phosphopeptide 





Rabbit polyclonal 1:1000 AB_331591
AKT COOH-terminus of mouse AKT AKT
Cell Signaling, 
catalog #9272
Rabbit polyclonal 1:1000 AB_329827
p-AS160
Synthetic peptide corresponding 






Rabbit polyclonal 1:1000 AB_10545274
AS160 EAITFTARKHPFPNEVSVDFC anti-TBC1D1




 Di Chiara et al. 
Am J Physiol 
Renal Physiol. 
309:F779, 2015




















Linked Whole Ab 
GE Healthcare, 
catalog #NA934
Sheep polyclonal 1:20000 AB_772206
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Table 3.  Plasma biochemistry and glucose homeostasis indexes in animals fed standard chow diet 
(SCD) or after 6 weeks with high-fat diet (HFD). Results are expressed as average ± SE (n, number of 
animals; *p<0.05, **p<0.01, ***p<0.001; unpaired t tests between genotypes in SCD or HFD). BW, body 
weight; FFAs, free fatty acids; HOMA, homeostatic model assessment; QUICKI, quantitative insulin 
sensitivity check index; T-Cholesterol, Total cholesterol; HDL-C, high-density lipoprotein cholesterol; 
VLDL-C, very low-density lipoprotein cholesterol. 
SCD HFD
Variable (units) WT Tg.sgk1 WT Tg.sgk1
Body weight (g) 25.49 ± 0.38; n=50 24.94 ± 0.48; n=56 31.51 ± 0.77; n=50 34.83 ± 0.76**; n=56
Lean tissue (g/BW) 0.41 ± 0.01; n=6 0.38 ± 0.01; n=6 0.58 ± 0.02; n=31 0.50 ± 0.01**; n=35
Fat tissue (g/BW) 0.24 ± 0.00; n=6 0.31 ± 0.02**; n=6 0.31  0.02; n=31 0.44  0.01***; n=35
Non-fasting insulin (ng/ml) 0.44 ± 0.07; n=8 0.48 ± 0.10; n=6 1.66 ± 0.15; n=6 5.51 ± 0.88**; n=6
Fasting insulin (ng/ml) 0.08 ± 0.04; n=7 0.04 ± 0.03; n=7 0.17 ± 0.03; n=7 1.09 ± 0.23**; n=11
Fasting glucose (mg/dl) 97.6 ± 4.7; n=7 129.0 ± 7.9**; n=11 158.0 ± 4.8; n=7 200.2 ± 14.4* n=10
HOMA-IR 0.4 ± 0.2; n=7 0.3 ± 0.2; n=7 1.7 ± 0.3; n=7 13.2 ± 2.9**; n=11
QUICKI 0.55 ± 0.13; n=7 0.82 ± 0.16; n=7 0.32 ± 0.01; n=7 0.26 ± 0.00**; n=12
T-Cholesterol (mg/ml) 62.86 ± 5.9; n=6 68.14 ± 10.25; n=6 110.8 ± 5.6; n=6 108.6 ± 2.9; n=6 
HDL-C (mg/ml) 59.6 ± 2.3; n=6 45.7 ± 4.0; n=6 114.5 ± 3.6; n=6 91.4 ± 7.7***; n=6 
VLDL-C (mg/ml) 2.5 ± 0.6; n=6 5.7 ± 1.0; n=6 3.1 ± 1.0; n=6 4.2 ± 0.5; n=6 
Triglycerides (mg/dl) 52.3 ± 8.0; n=6 84.8 ± 12.9; n=6 82.8 ± 9.8; n=6 123.7 ± 11.7*; n=6
FFAs (mmol/dl) 7.8 ± 1.0; n=6 8.8 ± 0.4; n=6 7.0 ± 0.8; n=6 8.0 ± 0.5; n=6
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